BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

Share this content:
Bendamustine with lenalidomide and dexamethasone demonstrated efficacy in patients with advanced R/R myeloma for certain patients.
Bendamustine with lenalidomide and dexamethasone demonstrated efficacy in patients with advanced R/R myeloma for certain patients.

The combination of bendamustine, lenalidomide, and dexamethasone (BRd) is safe and efficacious as second-line treatment for patients with relapsed/refractory multiple myeloma, a study published in the British Journal of Haematology has shown.1

Lenalidomide plus dexamethasone is a standard treatment regimen for patients with relapsed/refractory multiple myeloma; however, only a small proportion of patients will achieve high quality responses with this combination.

Bendamustine combined with lenalidomide and dexamethasone has demonstrated efficacy in patients with advanced relapsed/refractory myeloma, but its associated dose-limiting hepatotoxicity has limited its use to patients with heavily pretreated disease.

Therefore, investigators sought to evaluate the efficacy and safety of this 3-drug combination in patients with relapsed/refractory myeloma who have received only 1 prior line of therapy.

The multicenter, phase 2 study enrolled 50 patients who received induction therapy with bendamustine intravenously on days 1 and 2, lenalidomide orally daily for days 1 to 21, and dexamethasone on days 1, 8, 15, and 22, for 6 28-day cycles. Participants then received lenalidomide and dexamethasone alone for 12 cycles.

Results showed that 51% of the 45 evaluable patients achieved a complete response or a very good partial response. Median progression-free survival was 18.6 months (95% CI, 16.5-29.2) and median time to progression was 19.9 months (95% CI, 16.5-not reached).

Median overall survival has not yet been reached (95% CI, 37.7-not reached). Investigators estimated that 76% (95% CI, 64-91) of patients will be alive at 2 years.

Of note, researchers observed grade 4 neutropenia and thrombocytopenia in 34% and 16% of patients, respectively, despite pegfilgrastim support.


Mey UJM, Brugger W, Schwarb H, et al. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma – a phase II trial. Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14481. [Epub ahead of print]
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs